Result description
The Biobone Proof of Concept (POC) successfully characterized an innovative hydrogel from both a technical and business standpoint. This hydrogel, which functions without the addition of stem cells, is capable of regulating the immune response at the fracture site to actively promote osteogenesis. The field of application for this technology is vast, covering the entire orthopedic world. Our primary target audience includes polytrauma centers and orthopedic hospitals.
Our results have enabled us to identify a groundbreaking hydrogel capable of directly immunomodulating the inflammatory response at the site of bone fractures. This is a crucial breakthrough, as a prolonged or dysregulated inflammatory phase is a key barrier to effective bone regeneration.
What makes this finding truly remarkable is that this is achievable without the need for additional stem cells, which often come with significant side effects and logistical complexities. While cell-based therapies hold promise, they can be burdened by a high risk of contamination, the potential for unwanted immune reactions or uncontrolled growth, and considerable regulatory and cost hurdles.
By offering a cell-free yet biologically active solution, our hydrogel represents a new paradigm. It not only simplifies the treatment procedure and drastically reduces associated risks but also directly addresses a fundamental biological problem—the inflammatory cascade—paving the way for more predictable and efficient bone healing.
Addressing target audiences and expressing needs
- Grants and Subsidies
Following initial lab results, the project’s next phase is to replicate them in larger animal models. This is a crucial step toward clinical translation, as these models better mimic human anatomy and physiology. The goal is to confirm efficacy and safety, while studying the material’s behavior. The resulting data will form the core of the regulatory package, which is the mandatory path to turn a lab innovation into a clinically testable product.
- Public or private funding institutions
R&D, Technology and Innovation aspects
Once laboratory results have been achieved, the plan is to replicate the findings in larger animal models and in a pre-clinical setting.
Result submitted to Horizon Results Platform by DAY ONE SOCIETA A RESPONSABILITA LIMITATA